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Past experiments of the popular Aﬀymetrix (Aﬀy) microarrays have accumulated a huge amount of public data sets. To apply them
for more wide studies, the comparability across generations and experimental environments is an important research topic. This paper
particularly investigates the issue of cross-generation/laboratory predictions. That is, whether models built upon data of one generation
(laboratory) can diﬀerentiate data of another. We consider eight public sets of three cancers. They are from diﬀerent laboratories and are
across various generations of Aﬀy human microarrays. Each cancer has certain subtypes, and we investigate if a model trained from one
set correctly diﬀerentiates another. We propose a simple rank-based approach to make data from diﬀerent sources more comparable.
Results show that it leads to higher prediction accuracy than using expression values. We further investigate normalization issues in pre-
paring training/testing data. In addition, we discuss some pitfalls in evaluating cross-generation/laboratory predictions. To use data from
various sources one must be cautious on some important but easily neglected steps.
 2007 Elsevier Inc. All rights reserved.
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Gene expression proﬁling by DNA microarrays is a use-
ful tool in biological and clinical research. Superior to tra-
ditional biological experiments, it compares thousands of
genes simultaneously. With fast and systematic analysis1532-0464/$ - see front matter  2007 Elsevier Inc. All rights reserved.
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genes for certain diseases or build models for patient diag-
nosis/tumor classiﬁcation.
Though the microarray technology is popular, not many
institutions can conduct enough experiments for eﬀective
analysis due to the lack of patient samples or the high cost.
Studies in recent years have accumulated a huge amount of
microarray samples in public databases. If data experi-
mented under similar conditions can be combined together,
not only any laboratory can directly apply microarray tech-
nology in practical use, but also more extensive and reliable
studies are possible. The emergence of common guidelines
MIAME (Minimum Information About a Microarray
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cates the direction toward the universal use of public data.
The comparability of microarray experiments between
diversed sources and across distinct technologies is thus
an important research issue.
A microarray experiment from raw samples to expres-
sion values is a complicated procedure. Expression values
from various sources are not easily comparable. Many
recent studies explore the cross-platform comparability
between cDNA and oligonucleotide arrays, but so far con-
tradictive results have been reported. Even using the same
samples, some papers (e.g., [4,5]) conclude that measure-
ments from the two platforms are poorly correlated.
Though recent studies (e.g., [6–8]) give more promising
results, they still consider that the reproducibility across
platforms is not easily available.
For the same type of arrays, comparability issues also
occur. In particular, whether results from various genera-
tions of popular Aﬀymetrix (Aﬀy) human oligonucleotide
arrays can be used together is an issue. Though the same
platform tends to produce more consistent expression val-
ues, cross-generation and cross-laboratory use of Aﬀy
arrays remains a challenging task. This paper intends to
have a detailed investigation on this subject. Existing
papers of this topic mainly study the following three issues:
1. Whether diﬀerentially expressed genes identiﬁed across
two generations (laboratories) are similar or related.
2. Whether the same samples lead to similar expression val-
ues across two generations (laboratories).
3. Whether models built upon data of one generation (lab-
oratory) can diﬀerentiate data of another.
This paper focuses on studying the third issue.
Most work studying issue 1 concludes that genes identi-
ﬁed across generations (laboratories) are related (e.g., [9]).
In contrast, the other two issues are less settled. For issue 2,
one of the ﬁrst studies is [10]. Using the same samples on
two generations, it reports that better similarity of the
probe sets leads to higher correlation between expression
values. References [11,12] further strengthen this ﬁnding
by showing that considering only probes with overlapping
sequences gives excellent comparability. However, even
with these studies, some still doubt the reproducibility of
expression values across generations, so several papers pro-
pose more sophisticated techniques. By calculating expres-
sion changes at the probe-level, Elo et al. [13] report that
such information gives better comparability. Bhattacharya
and Mariani [14] propose regression models, which reﬂect
the relationship between expression values of two
generations.
Compared to issue 2, issue 3 concerns more about the
practical use of data from diﬀerent sources. Many applica-
tions such as cancer diagnosis and tumor classiﬁcation are
of this type. If data of other laboratories can be used, an
institution can classify its patient samples without huge ini-
tial experiments/costs. Some have checked issue 3: Bloomet al. [15] collect samples of 21 tumor types across diﬀerent
laboratories and two Aﬀy generations. They normalize
expression values of various sources and apply an Artiﬁcial
Neural Networks (ANN) model. High prediction accuracy
(88%) is reported. Jiang et al. [16] consider lung cancer data
sets across two generations. They develop special data
transformation and report high prediction accuracy. Xu
et al. [17] study prostate cancer samples across diﬀerent
laboratories but under the same Aﬀy generation. Using a
classiﬁer based on only two genes, a model built on data
from three laboratories successfully separates a test set
from another laboratory to normal or cancer. Some other
related papers are references [1,2].
This papermakes the following two contributions regard-
ing cross-laboratory and cross-generation predictions:
1. We investigate whether expression values are reliable for
the prediction tasks. In cross-platform analysis (e.g.,
cDNA and oligonucleotide), quite a few (e.g., [18,19])
observe inconsistent expression values, so they use infor-
mation less dependent on the scale of values (e.g., rank
levels). While expression values seem to be more consis-
tent if only Aﬀy arrays are considered, it is essential to
check which way is better. We propose a rank-based
approach and compare it with using expression values.
2. We present a correct way of evaluating cross-laboratory
and cross-generation predictions. Some earlier papers
(e.g., [15,19,20]) mix data across various generations
(or platforms), and then split the set to training/testing.
We point out that such a mechanism sometimes overes-
timates the accuracy. A correct evaluation should have
the training set independent of the generation (platform)
of the test data.
This paper does not touch cross-platform issues (e.g.,
cDNA vs. Aﬀy). For a more complete account of cross-
platform predictions, see [19] and references therein.
2. Methods
Fig. 1 outlines our approach. Data sets of three cancer
types, made of Aﬀy human oligonucleotide microarrays,
are from diﬀerent generations and/or laboratories. The
expression values are downloaded from public web sites.
In each experiment two sets of the same cancer type are
used as training/prediction sets. To take into account the
variability of expression values, all samples are normalized
so that the mean of expression values over all genes is a
speciﬁed constant. We identify common genes among dif-
ferent chip generations. Then an optional step is to trans-
form expression values to rank levels. For the training set
we apply SAM (Signiﬁcance Analysis of Microarrays)
[21] to obtain diﬀerentially signiﬁcant genes. The classiﬁca-
tion analysis is performed by applying k-Nearest Neigh-
bors (KNN) [22]. A leave-one-out cross-validation (LOO
CV) procedure obtains a suitable parameter k. The entire
process is repeated for any pair of sets as training/testing.
SAM
Significant genesSignificant genes
Samplewise
normalization
Samplewise
normalization
Testing Set
Prediction results
Parameter selected by LOO CV
Training Set
Model from    –Nearest Neighborsk
Rank level (optional)
Common genes Common genes
Rank level (optional)
Fig. 1. Workﬂow of the analysis. The width of each box reﬂects the
number of genes. Details are in the beginning of Section 2. Note that in
this paper we compare whether using expression values or transforming
them to rank levels is better. Thus ‘‘Rank level’’ is marked as ‘‘optional’’
as it is applied only to the latter.
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included in the R-project [23]. Details of our methods are
described in the following subsections.2.1. Microarray data collection and preprocessing
To conduct the integrated, cross-generation and cross-
laboratory predictions of Aﬀy human arrays, we select
public data of three cancer types. The ﬁrst type, acute lym-
phoblastic leukemia (ALL), includes two data sets of diﬀer-
ent generations published from the same laboratory. The
data set of Yeoh et al. [24], from HG-U95Av2 array, is
denoted as ALL-95. Another data set of Ross et al. [25],
from HG-U133A array, is called ALL-133. It has 132 sam-
ples from the original 335 HG-U95Av2 data obtained by
Yeoh et al. To generate an independent source, ALL-95
includes only 203 non-replicated cases. The subtypes to
be predicted are ALLs with deﬁned recurrent chromosomal
aberrations: t(12;21), t(1;19) and hyperdiploid with more
than 50 chromosomes (HD > 50). The second cancer type
is acute myeloid leukemia (AML). Three data sets are gen-
erated by three diﬀerent institutions using HG-U133A
chips: The set Ross et al. [26], abbreviated as AML-1, is
a childhood study. The other two studies, AML-2 (Valk
et al. [27]) and AML-3 (Gutie´rrez et al. [28]), involve adult
samples. The predicted subtypes are AMLs with t(8;21),
inv(16) and t(15;17). These biologically distinct subtypes
are identical both in pediatric and adult AMLs. The
last group is breast cancer. Three data sets across three
generations of chips (HuGeneFL, HG-U95Av2 and
HG-U133A) are collected from three diﬀerent institutions.
They are denoted as Breast-FL (West et al. [29]), Breast-95
(Huang et al. [30]) and Breast-133 (Wang et al. [31]),
according to the generation of chip used in each individual
study. The estrogen receptor (ER) status (positive or nega-
tive) is the variable to be predicted. Table 1 summarizes keycharacteristics and URL addresses of all the eight micro-
array data sets.
After expression values are downloaded from the
referred public websites, values of each array are rescaled
by setting the 2% trimmed mean of all the genes in an array
to be 500, as suggested in the Aﬀy Microarray Suite 5.0
(MAS 5.0) program.
2.2. Gene mapping (common probe sets identiﬁcation)
According to their launch time, the three array genera-
tions can be aligned as the order of HuGeneFL,
HG-U95Av2, and HG-U133A. Because of multiple design
advances used to produce newer Aﬀy human arrays, many
probe sets diﬀer between generations of arrays. For a com-
parative analysis, it is critical to identify a subset of com-
mon genes. One approach is to match the UniGene IDs
among genes. Each UniGene ID corresponds to a cluster
containing sequences that represent a unique gene and its
related information [32]. However, diﬀerent UniGene
Builds are used for the three Aﬀy generations. Some Uni-
Gene IDs cannot be exactly tracked between two Builds.
An alternative method considers LocusLink (currently
implemented as Entrez Gene [33]), and it does not suﬀer
from the same problem as much. Another popular method
uses matching tables provided by Aﬀymetrix. The
matching between two generations of arrays is based on
the similarity of sequence information of probe sets
(http://www.aﬀymetrix.com/support/technical/comparison_
spreadsheets.aﬀx). According to diﬀerent constructions,
there are two mappings called ‘‘Good Match’’ and ‘‘Best
Match’’. The latter, obtained under a more stringent crite-
rion than the former, chooses probe sets with the greatest
likelihood of representing the same gene across generations
[34].
Hwang et al. [11] test methods of UniGene IDs, Locu-
sLink IDs and Best Match to match genes between
HG-U95Av2 and HG-U133A arrays. They experimented
with 14 samples on both generations of arrays. Correlation
coeﬃcients indicate that Best Match demonstrates higher
reproducibility than the other two methods. In this study,
we thus adopt the method of Best Match for gene
mapping between HG-U95Av2 and HG-U133A. Most
probe sets between these two generations have one-to-one
correspondence. For few multiple (HG-U95Av2)-to-one
(HG-U133A) mappings, we select the ﬁrst HG-U95Av2
probe set in the Aﬀy comparison spreadsheet to make
them one-to-one. Though Aﬀymetrix also provides a com-
parison table for HuGeneFL and HG-U95Av2 (http://
www.aﬀymetrix.com/Auth/support/downloads/compari-
sons/PN600444HumanFLComp.zip), Best Match is not
deﬁned and multiple-to-one relations are not directly avail-
able. The situation for HuGeneFL and HG-U95Av2 is
thus more complicated as multiple-to-multiple relations
occur. To generate matched probe sets, we follow previous
studies [10,14,16] and have the following procedure. For
any given HuGeneFL probe set, from its corresponding
Table 1
Key characteristics of all analyzed data
Study referencea Institutionb Microarray generation No. of samples Cancer subtypes for analysis
{# in the subtype}
Acute lymphoblastic leukemia (ALL)
Yeoh et al. [24] (ALL-95) SJCRH U95Av2 203c t(12;21) {59}
HD > 50 {47}
t(1;19) {9}
Ross et al. [25] (ALL-133) SJCRH U133A 132 t(12;21) {20}
HD > 50 {17}
t(1;19) {18}
Acute myeloid leukemia (AML)
Ross et al. [26] (AML-1) SJCRH U133A 130 t(15;17) {15}
inv(16) {14}
t(8;21) {21}
Valk et al. [27] (AML-2) Erasmus MC U133A 285 t(15;17) {18}
inv(16) {19}
t(8;21) {22}
Gutie´rrez et al. [28] (AML-3) Salamanca U133A 43 t(15;17) {10}
inv(16) {4}
t(8;21) {0}
Breast cancer
West et al. [29] (Breast-FL) DUMC HuGeneFL 49 ER+ {25}
ER {24}
Huang et al. [30] (Breast-95) KF-SYSCC U95Av2 89 ER+ {74}
ER {15}
Wang et al. [31] (Breast-133) Erasmus MC U133A 286 ER+{209}
ER {77}
a URLs of data sets:
ALL-95: http://www.stjuderesearch.org/data/ALL1/index.html
ALL-133: http://www.stjuderesearch.org/data/ALL3/index.html
AML-1: http://www.stjuderesearch.org/data/AML1/index.html
AML-2: ftp://ftp.ncbi.nih.gov/pub/geo/data/geo/raw_data/series/GSE1159/GSE1159_RAW.tar
AML-3: ftp://ftp.ncbi.nih.gov/pub/geo/data/geo/raw_data/series/GSE1729/GSE1729_RAW.tar
Breast-FL: http://data.cgt.duke.edu/west.php
Breast-95: http://data.cgt.duke.edu/lancet.php
Breast-133: ftp://ftp.ncbi.nih.gov/pub/geo/data/geo/by_series/GSE2034_family.soft.gz.
b SJCRH, St. Jude Children’s Research Hospital; Erasmus MC, Erasmus University Medical Center; Salamanca, Hospital Universitario de Salamanca;
DUMC, Duke University Medical Center; KF-SYSCC, Koo Foundation Sun Yat-Sen Cancer Center.
c Exclusion of overlapping cases with ALL-133.
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overlap percentage in the column of ‘‘old (HuGe-
neFL)ﬁ new (HG-U95Av2) sequence relationship’’. This
procedure leads to multiple (HuGeneFL)-to-one (HG-
U95Av2) matchings. We then select the ﬁrst of the multiple
HuGeneFL probe sets to have one-to-one relationships.
This step is the same as how we process HG-U95Av2
and HG-U133A arrays. Finally, we get a list of 5979
common probe sets between HuGeneFL and HG-
U95Av2, and a list of 9530 probe sets between HG-
U95Av2 and HG-U133A. The intersection of the above
two lists gives 5045 probe sets, which are shared across
three generations.2.3. Rank-based normalization
Previous work has shown that considering a gene’s
rank within a chip instead of using its expression value
better eliminates systematic biases and thus improvesthe classiﬁcation accuracy [17,19,20]. There are some
variants of the rank-based normalization. The simplest
one replaces the expression value of a gene with its rank
among expression values of a single chip [35,36]. This
method is considered in our study. Quantile normaliza-
tion is another rank-based approach [37,38]. It calculates
a value for each rank level by taking the average of the
expression values of that particular rank in available
arrays, and then replaces the expression value of each
gene by the associated reference value of its rank. Med-
ian rank scores is also a rank-based approach. This var-
iant derives the median of each gene among the available
arrays and sorts those medians as the reference value of
a particular rank [19,20]. Tsodikov et al. [35] show that
replacing expression values by ranks performs well in
terms of selecting diﬀerentially expressed genes. Qiu
et al. [38] also reveal that this simple scheme outperforms
the quantile normalization method in reduction of
between-gene dependence and identiﬁcation of diﬀerential
574 H.-C. Liu et al. / Journal of Biomedical Informatics 41 (2008) 570–579genes. Thus in this work we investigate if a direct
replacement of expressions by ranks is eﬀective in
cross-generation and cross-laboratory comparisons.
Below we provide details of the adopted procedure.
First of all, we obtain common genes from data of
each cancer type. The rank-based normalization method
then replaces the value of each probe set with its rank
in the set of common genes. Next, gene selection is per-
formed with SAM (Signiﬁcance Analysis of Micro-
arrays) [21] to identify the list of diﬀerentially
expressed genes based on the training data set of each
experiment. When applying SAM for gene selection,
the parametric statistical test (t-test) is used. For other
parameters, ‘‘Two class unpaired’’ is selected as the
response type, while the number of permutation and
the number of KNN neighbors are set as 300 and 10,
respectively. Besides, the logged ﬂag is turned oﬀ. The
FDR (false discovery rate) is set as 5%. As far as the
testing data is concerned, the same procedure of replac-
ing expression values with ranks is applied. After that,
the list of diﬀerential probe sets selected based on the
training data set ﬁlters out unwanted probe sets in the
testing data set.Table 2
A comparison of cross-generation/laboratory predictions: using rank levels an
Trainingﬁ Testing Cancer subtype Accur
Rank
Acute lymphoblastic leukemia (ALL)
ALL-95ﬁ ALL-133 t(12;21) 96.2
HD > 50 91.6
t(1;19) 100
ALL-133ﬁ ALL-95 t(12;21) 97.0
HD > 50 95.0
t(1;19) 99.5
Acute myeloid leukemia (AML)
AML-1ﬁ AML-2 t(15;17) 99.2
t(8;21) 100
inv(16) 97.8
AML-1ﬁ AML-3 t(15;17) 100
inv(16) 97.6
AML-2ﬁ AML-1 t(15;17) 100
t(8;21) 99.2
inv(16) 99.2
AML-2ﬁ AML-3 t(15;17) 97.6
inv(16) 97.6
AML-3ﬁ AML-1 t(15;17) 99.2
inv(16) 90.0
AML-3ﬁ AML-2 t(15;17) 99.6
inv(16) 98.2
Breast cancer
Breast-FLﬁ Breast-95 ER 86.5
Breast-FLﬁ Breast-133 ER 89.2
Breast-95ﬁ Breast-FL ER 87.8
Breast-95ﬁ Breast-133 ER 86.4
Breast-133ﬁ Breast-FL ER 85.7
Breast-133ﬁ Breast-95 ER 86.5
In each row, we boldface the value which gives higher accuracy (true positive2.4. Predictions
In each experiment, one data set from Table 1 is for
training and another data set (across generations or labora-
tories) is for testing. The k-Nearest Neighbors (KNN) [22]
is employed in the prediction task. For any instance in the
test set, KNN predicts its class by the majority class of its k
closest neighbors in the training set. The distance between
any two data instances is by the Euclidean metric. Since the
performance of KNN depends on the parameter k, in data
classiﬁcation one usually implements a validation proce-
dure to select it. Here we consider leave-one-out cross-val-
idation (LOO CV). For any given k, LOO CV sequentially
singles one training instance out for validation. That is,
KNN predicts this instance by checking its neighbors in
the remaining set. The value k with the best LOO CV accu-
racy is then applied to predict the independent testing data.
In our experiments, we consider odd integers from 1 to 17
to search for the best k. Values beyond this range do not
give better LOO CV. In addition to KNN, we also con-
ducted preliminary experiments using support vector
machines (SVM). Results are similar, so subsequently we
discuss only results of using KNN.d expression values (Exp. val.)
acy True positive rate
Exp. val. Rank Exp. val.
68.1 75.0 75.0
92.4 94.4 94.4
97.7 100 83.3
93.1 100 91.5
87.1 78.7 74.4
98.5 88.8 77.7
99.2 94.4 88.8
99.6 100 100
91.2 100 36.8
95.3 100 80.0
88.3 100 50.0
100 100 100
96.9 95.2 80.9
90.7 92.8 21.4
93.0 90.0 90.0
95.3 75.0 50.0
100 100 100
89.2 7.1 0
97.1 100 66.6
93.3 94.7 0
83.1 73.3 80.0
81.1 78.0 80.5
53.1 95.8 41.7
75.2 79.2 10.4
75.5 75.0 54.2
83.1 40.0 40.0
rate).
Table 3
A comparison of rank levels and expression values (Exp. val.) by
randomly splitting each data set to training (two thirds) and testing (one
third)
Data Cancer subtype Accuracy True positive rate
Rank Exp. val. Rank Exp. val.
Acute lymphoblastic leukemia (ALL)
ALL-95 t(12;21) 97.7 85.7 99 80
HD > 50 94.4 94.2 84.3 82.5
t(1;19) 100 99.1 100 80
ALL-133 t(12;21) 98.8 95.7 100 100
HD > 50 97.4 94.7 90 73.3
t(1;19) 97.7 93.6 100 81.6
Acute myeloid leukemia (AML)
AML-1 t(15;17) 100 97.4 100 82
t(8;21) 96.1 86.1 95.7 65.7
inv(16) 96.1 87.2 94 24
AML-2 t(15;17) 99.6 99.1 100 90
t(8;21) 100 98.5 100 88.7
inv(16) 98.1 95.6 100 64.2
AML-3 t(15;17) 100 96.6 100 90
inv(16) 85.9 87.9 0 10
Breast cancer
Breast-FL ER 89.3 88.0 88.6 84.3
Breast-95 ER 81.1 79.7 20.0 10.0
Breast-133 ER 84.9 83.4 67.0 62.6
In each row, we boldface the value which gives higher accuracy (true
positive rate).
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We conduct experiments on three cancer types of data
sets, which are summarized in Table 1. This section ﬁrst
compares prediction results under two ways of processing
arrays: one directly uses gene expression values, and the
other transforms expression values to rank levels. The
experimental procedure has several variants of normaliza-
tion, so subsequently we check their respective eﬀects.
Finally, we discuss how the cross-validation analysis might
mislead the conclusion about the performance of cross-
generation/laboratory predictions.
3.1. A comparison between using expression values and rank
information
To perform cross-generation/laboratory predictions,
one can prepare training and testing data by directly using
expression values of signiﬁcant genes. However, the scale
of each gene may vary due to diﬀerent chip generations
or experimental environments. We can instead use each
gene’s rank in the same subset of signiﬁcant genes. Exper-
iments below compare which method is better.
For any cancer type, each experiment considers one sub-
type as the target prediction label. A data set of this cancer
type is used as the training data of two classes: whether an
array is associated with the speciﬁed subtype or not. For
each array in another set (called testing data), we then pre-
dict its class label and calculate the accuracy. This proce-
dure is repeated for every two sets of the same cancer
type. One exception is that AML-3 has no t(8;21) arrays,
so for this subtype AML-3 is not used as the testing set.
Except the diﬀerence on using expression values or rank
levels, all other settings follow the procedure in Fig. 1.
Table 2 gives results of the comparison. Some cancer sub-
types have very few arrays in both training and testing sets,
so we have the so called ‘‘unbalanced problems’’ in data
classiﬁcation. Accuracy may not be the best evaluation cri-
terion in such situations. Predicting everything not in the
speciﬁed subtype yields a high but misleading accuracy
value. Thus Table 2 also presents the true positive rate,
which is
Number of correctly predicted data in the subtype
Number of data in the subtype
:
This measurement better reveals the performance on iden-
tifying the speciﬁed subtype. For example, when training
AML-2 (by expression values) to identify the subtype
inv(16), the prediction of AML-1 is erroneous (21.4% true
positive rate in Table 2), but the accuracy is very high
(90.7%). Since breast cancer without ER (ER) is consid-
ered poorly response to treatment, we report ER as posi-
tive prediction.
Table 2 clearly shows that using the ranks of the selected
genes within an array consistently produces better results
than using the original expression values. For ALL and
AML, the prediction by using rank levels is excellent.One exception is to predict inv(16) by using AML-3 as
the training set. Since AML-3 contains only four inv(16)
arrays, there is no enough information to discriminate this
subtype from others.
Both methods give worse accuracy in predicting breast
cancer subtypes. As indicated earlier, three data sets of this
cancer type are the most heterogeneous. They are cross-
generation as well as cross-laboratory, but ALL sets are
cross-generation only and AML sets are cross-laboratory
only. Training Breast-95 to classify the other two sets gives
much lower accuracy than other cases. We suspect the rea-
son is that Breast-95 is the most unbalanced (74 ER+ and
15 ER arrays) among the three breast cancer sets.
To check if in typical microarray comparisons the pro-
posed rank-based approach is more robust than using
expression values, we also conduct experiments on each
data set alone, by randomly separating each data set into
a training set (two thirds) and an independent testing set
(one third). This procedure is repeated ten times in each
experiment, and the average accuracy is reported in Table
3. We again ﬁnd that using ranks leads to higher accuracy.
Though our procedure in Fig. 1 is rather simple, steps
such as selecting diﬀerential genes are important. Table 4
presents results without removing any genes. The accuracy
is generally lower than that in Table 2. Thus even if expres-
sion values have been transformed to rank levels, selecting
important genes is still essential.
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levels
While Table 2 indicates that rank levels are better than
expression values, we investigate if the same conclusion
stands after slight changes of the experimental procedure.
One issue we intend to study is the eﬀect of gene-wise nor-
malization. That is, after selecting signiﬁcant genes, forTable 4
A comparison between variants of the experimental procedure: The ﬁrst two
Gene selection Y Y
Genewise normalization Y
Trainingﬁ Testing Subtype Rank
Acute lymphoblastic leukemia (ALL)
ALL-95ﬁ ALL-133 t(12;21) 96.9 9
HD > 50 93.1 9
t(1;19) 100 10
ALL-133ﬁ ALL-95 t(12;21) 97.5 9
HD > 50 94.5 9
t(1;19) 99.5 9
Acute myeloid leukemia (AML)
AML-1ﬁ AML-2 t(15;17) 99.6 9
t(8;21) 100 10
inv(16) 98.2 9
AML-1ﬁ AML-3 t(15;17) 97.6 10
inv(16) 97.6 9
AML-2ﬁ AML-1 t(15;17) 100 10
t(8;21) 99.2 9
inv(16) 96.9 9
AML-2ﬁ AML-3 t(15;17) 97.6 9
inv(16) 97.6 9
AML-3ﬁ AML-1 t(15;17) 99.2 9
inv(16) 89.2 9
AML-3ﬁ AML-2 t(15;17) 97.8 9
inv(16) 94.0 9
Breast cancer
Breast-FLﬁ Breast-95 ER 84.3 8
Breast-FLﬁ Breast-133 ER 85.7 8
Breast-95ﬁ Breast-FL ER 81.6 8
Breast-95ﬁ Breast-133 ER 80.1 8
Breast-133ﬁ Breast-FL ER 87.8 8
Breast-133ﬁ Breast-95 ER 82.0 8
In each row, we boldface the value which gives the highest accuracy and unde
a
Fig. 2. Distributions of arrays from two diﬀerent data sets. Data set A: n (clas
possible practical situation: information from one set cannot discriminate posi
combined set is high.each gene we normalize ranks or expression values in all
training arrays to have mean zero and standard deviation
one. In data classiﬁcation such a procedure is called feature
scaling (normalization). The purpose is to avoid the possi-
ble dominance of genes having large values. The same scal-
ing factors are then employed to normalize the testing
data. Table 4 lists accuracy with and without gene-wise
normalization. Using expression values, the accuracy withrows list diﬀerent settings
Y Y
Y
Exp. val.
6.2 87.1 98.4 68.1 80.3
1.6 93.9 97.7 92.4 81.8
0 86.3 99.2 97.7 86.3
7.0 92.6 97.5 93.1 79.3
5.0 94.0 78.3 87.1 82.2
9.5 99.5 99.5 98.5 98.0
9.2 99.2 98.9 99.2 89.8
0 99.6 100 99.6 91.9
7.8 88.0 98.5 91.2 92.9
0 100 95.3 95.3 86.0
7.6 95.3 100 88.3 88.3
0 99.2 100 100 93.8
9.2 98.4 98.4 96.9 84.6
9.2 99.2 98.4 90.7 88.4
7.6 95.3 95.3 93.0 81.3
7.6 95.3 100 95.3 90.6
9.2 95.3 97.6 100 78.4
0.0 90.7 92.3 89.2 89.2
9.6 96.4 97.1 97.1 93.6
8.2 94.7 95.0 93.3 93.3
6.5 68.5 84.3 83.1 80.9
9.2 57.3 85.0 81.1 82.2
7.8 59.2 51.0 53.1 51.0
6.4 73.1 72.7 75.2 73.1
5.7 85.7 53.1 75.5 81.6
6.5 85.4 82.0 83.1 85.4
rline the one with the lowest accuracy.
b
s I), h (class II). Data set B: m (class I), n (class II). (a) Ideal situation; (b)
tive/negative arrays of another set. However, the LOO CV accuracy of the
H.-C. Liu et al. / Journal of Biomedical Informatics 41 (2008) 570–579 577normalization is slightly improved for ALL and AML, but
is worse for some cases of breast cancer. Thus one cannot
conclude that this normalization is always helpful. For
rank levels, the accuracy with/without gene-wise normali-
zation is very similar. It consistently outperforms expres-
sion values no matter the gene-wise normalization is
performed or not. Overall this normalization has a bigger
eﬀect on using expression values than rank levels.3.3. Pitfalls of reporting cross-validation accuracy
To evaluate the performance of cross-laboratory/gener-
ation predictions, earlier we trained data from one source
and classiﬁed another. However, some studies report the
prediction accuracy based on a cross-validation analysis
(e.g., [15,19,20]). They pool arrays from diﬀerent data sets
and randomly split the combined set to training and valida-
tion sets. Here we argue that the performance of cross-val-
idation analysis should be used in a more careful way when
dealing with data sets from diﬀerent sources. In this type of
studies, we expect that arrays from distinct data sets can be
merged in the way shown in Fig. 2(a). That is, arrays asso-
ciated with the same class but diﬀerent data sets are clus-
tered together. Thus for any given array one canTable 5
A comparison of two evaluation methods for cross-generation/laboratory pre
Leave-one-out
Combined set Subtype Acc. TP
Acute lymphoblastic leukemia (ALL)
ALL-95 + ALL-133 t(12;21) 89.5 83
HD > 50 96.1 83
t(1;19) 99.1 92
Acute myeloid leukemia (AML)
AML-1 + AML-2 t(15;17) 99.2 93
t(8;21) 97.3 83
inv(16) 97.8 84
AML-1 + AML-3 t(15;17) 100 100
inv(16) 93.6 66
AML-2 + AML-3 t(15;17) 99.3 96
inv(16) 98.4 95
Breast cancer
Breast-FL + Breast-95 ER 87.7 74
Breast-95 + Breast-133 ER 81.9 43
Breast-133 + Breast-FL ER 84.2 69
Left: LOO CV accuracy by combining data from two sources. Right: accuracy o
used, so the last column is the same as that of Table 2. Acc. and TP mean a
signiﬁcantly lower than that by LOO CV is bold-faced.correctly predict its class label. However, it is observed in
our study that arrays from two sources may appear in a sit-
uation similar to Fig. 2(b). In this example, arrays of one
data set are close to each other, so it is diﬃcult to separate
arrays in the combined set via their class labels. Training
one data set to classify another would result in erroneous
predictions. However, for this example, LOO CV accuracy
via KNN (or other classiﬁcation methods) is excellent. For
any array singled out for validation, its closest neighbors
are arrays in the same class of the same set. Therefore,
cross-validation accuracy may overestimate the practical
performance of cross-generation/laboratory predictions.
In such studies training and testing sets should be from
independent sources.
To illustrate the possible overestimation of cross-valida-
tion accuracy, Table 5 reports LOO CV accuracy on the
combined set of every two sources of the same cancer type.
We compare it with the two accuracy values of training one
and predicting another. Here expression values are used, so
the last column of Table 5 is the same as the result in Table
2. In all situations, CV values are either equally good or
much better. Therefore, experimental results based on
cross-validation analyses may mislead the predicting power
of the data.dictions
Independent
Trainingﬁ Testing Acc. TP
.5 ALL-95ﬁ ALL-133 68.1 75.0
ALL-133ﬁ ALL-95 93.1 91.5
.0 ALL-95ﬁ ALL-133 92.4 94.4
ALL-133ﬁ ALL-95 87.1 74.4
.5 ALL-95ﬁ ALL-133 97.7 83.3
ALL-133ﬁ ALL-95 98.5 77.7
.9 AML-1ﬁ AML-2 99.2 88.8
AML-2ﬁ AML-1 100 100
.7 AML-1ﬁ AML-2 99.6 100
AML-2ﬁ AML-1 96.9 80.9
.8 AML-1ﬁ AML-2 91.2 36.8
AML-2ﬁ AML-1 90.7 21.4
AML-1ﬁ AML-3 95.3 80.0
AML-3ﬁ AML-1 100 100
.6 AML-1ﬁ AML-3 88.3 50.0
AML-3ﬁ AML-1 89.2 0
.4 AML-2ﬁ AML-3 93.0 90.0
AML-3ﬁ AML-2 97.1 66.6
.6 AML-2ﬁ AML-3 95.3 50.0
AML-3ﬁ AML-2 93.3 0
.4 Breast-FLﬁ Breast-95 83.1 80.0
Breast-95ﬁ Breast-FL 53.1 41.7
.5 Breast-95ﬁ Breast-133 75.2 10.4
Breast-133ﬁ Breast-95 83.1 40.0
.3 Breast-133ﬁ Breast-FL 75.5 54.2
Breast-FLﬁ Breast-133 81.1 80.5
f predicting one data set after training another. Here expression values are
ccuracy and true positive rate, respectively. Accuracy (true positive rate)
578 H.-C. Liu et al. / Journal of Biomedical Informatics 41 (2008) 570–5794. Conclusions
We conduct a detailed study on cross-generation and
cross-laboratory predictions of Aﬀy microarray data. A
focus is on investigating if using expression values is suit-
able. Experiments show that an alternative way of using
simple rank levels gives more stable prediction results.
We also discuss some pitfalls in evaluating cross-genera-
tion/laboratory predictions.
The framework proposed in this paper is rather simple.
As more studies involve such cross-generation and cross-
laboratory predictions, we expect our approach to be very
useful. For example, existing data can be trained to predict
arrays from a new generation of Aﬀymetrix human oligo-
nucleotide array, Plus 2.0. Future work includes experi-
ments on more cancer types or future Aﬀy generations.
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